Nanotechnology and Skin Delivery: What "Nano" Actually Does Depends on the Formula Around It

A cosmetic chemist who says a nanoparticle "delivers" an active into skin is usually describing two different things with one word. According to reporting in Cosmetics & Toiletries's piece "Nanotechnology and Skin Delivery: Infinitely Small or Infinite Possibilities?", most nanomaterials used in cosmetics, including metal oxides like titanium dioxide and zinc oxide, are too rigid and too large to cross the stratum corneum at all. What they do instead is settle into skin furrows, ridges, and the mouths of hair follicles, forming a surface depot rather than a route into viable tissue. Flexible lipid vesicles are a separate category built for the opposite job, engineered specifically to slip between corneocytes. Treating both as one "nano" story is where a lot of marketing copy, and a fair amount of consumer anxiety, goes wrong.

That distinction only matters because delivery in a real formula is never a solo act. A liposome or nanocapsule has to survive alongside emulsifiers that determine whether it stays intact in an oil-water system, humectants and thickeners that set the viscosity it has to migrate through, and preservatives that must not destabilize its bilayer before it ever reaches skin. The vesicle is the headline ingredient; the surrounding base decides whether it does anything at all. That's the architecture question this desk cares about, and it's also the one a single-ingredient nanotech story tends to skip.

The lipid-vesicle side of this has been a commercial reality for close to forty years, not a recent innovation. Liposomes were first described in the mid-1960s, and Christian Dior brought the first liposome-based cosmetic, Capture, to market in 1986, built on work by Gérard Redziniak and Alain Meybeck in Dior's labs. L'Oréal followed with synthetic "niosome" vesicles in the 1970s, a 1980 patent on vectorized actives, and polymeric nanocapsules in 1998's Plénitude Revitalift. That history undercuts any framing of encapsulated delivery as an untested trend; the open questions today are less about whether vesicles can carry an active and more about which base chemistries let them do it reliably at scale.

The particulate side of the nanotech conversation is where the science gets more granular, and where headline claims about "non-penetration" tend to flatten real variation. Human studies have rarely detected titanium dioxide nanoparticles below the outer stratum corneum, and when they do turn up deeper, it's concentrated around hair follicles rather than diffused through intact corneocyte layers. Zinc oxide behaves similarly at the surface but has drawn more specific safety scrutiny: some research has linked deep follicular accumulation of zinc oxide nanoparticles to apoptosis in hair follicle stem cells, a finding that's more consequential than a blanket "doesn't penetrate, so it's safe" line. Location on the body changes the picture too, since forehead and calf skin carry far denser follicular openings than the forearm, meaning a penetration study on one site doesn't generalize cleanly to a full-body product claim. Follicular reservoirs also clear slowly, only as hair grows and sebum turns over, so "stays on the surface" and "clears quickly" are not the same claim.

Regulators have responded to that nuance by tightening the assessment framework rather than settling on a single verdict. The Scientific Committee on Consumer Safety's 2023 guidance for nanomaterial safety dossiers added new sections chemists now have to address, including solubility and dissolution rate, evidence for the absence of nanoparticles in an ingredient batch, particle aspect ratio, and endocrine-disruption and reproductive-toxicity screens. The European Commission acted on some of that evidence directly this year: Regulation 2024/858 banned or restricted twelve nanomaterials across five groups, including gold, platinum, and certain copolymers, with the ban on placing those materials on the market taking effect February 1, 2025, and a further restriction on distribution and retail sell-through following November 1, 2025. Formulators reformulating around those materials aren't just swapping an ingredient; they're re-testing how the replacement behaves inside the same emulsifier and preservative system that made the original nanomaterial stable.

The United States has taken a different route entirely, and the gap is a formulation-strategy problem as much as a legal one. The FDA's cosmetics guidance on nanomaterials, finalized in 2014, is non-binding, with no mandatory pre-market notification or nano-specific labeling requirement. Nano titanium dioxide and zinc oxide in sunscreens were reaffirmed as generally recognized as safe and effective in FDA's 2021 sunscreen monograph review, after the agency worked through more than 1,200 studies. A sunscreen formulated once can face EU notification and "(nano)" labeling obligations under Regulation (EC) 1223/2009 on one side of the Atlantic and no equivalent disclosure requirement on the other, which means the underlying formula, not just its marketing, sometimes has to be built in region-specific versions to satisfy each regime.

None of this resolves into a tidy verdict on whether nanotechnology delivers on its promise in skin care, and that's arguably the more honest place to leave it. A liposome carrying retinol through a well-built emulsion is doing real, measurable work; a zinc oxide particle sitting in a hair follicle for weeks is doing something else, neither delivery nor inert decoration. The formula around each one, from the emulsifier holding it in suspension to the preservative keeping the whole system stable long enough to reach a shelf, is what turns either scenario into a finished product rather than a lab curiosity.